Takeda announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. The leadership changes, unless otherwise noted, will be effective at the start of Takeda's fiscal year 2022 (April 1, 2022) and these executives will report to President and CEO Christophe Weber: Gabriele Ricci, who formerly served as Head of IT for the Plasma-Derived Therapies (PDT) Business Unit has been appointed Takeda's Chief Data and Technology Officer, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company's Data, Digital and Technology division.

Elevating and evolving the company's existing IT function demonstrates the company's commitment to creating andata and technology approach to ultimately help better deliver life-transforming treatments to patients and society. Ramona Sequeira, who currently serves as President of the U.S. Business Unit and Global Portfolio Commercialization, has been appointed President, Global Portfolio Division. This newly created division in Takeda will bring together three global teams and three regional businesses to ensure the company can successfully bring new and existing global products to patients.

Specifically, Ramona will have oversight over Global Medical, Global Product Launch Strategy, the Vaccine Business Unit as well as three regional business units including Europe and Canada, Growth and Emerging Markets and the China Business Unit. Julie Kim, who is currently President of the PDT Business Unit, has been appointed President of the U.S. Business Unit and U.S. country head. In this role, Julie will focus on continuing to grow Takeda's business in the U.S., a key market for the company's success.

Giles Platford, who is currently President of the Europe and Canada Business Unit, has been appointed President of the PDT Business Unit, which will remain one of the most important growth drivers of revenue for Takeda over the coming years. In addition, Takeda will expand the roles of other executive team members, including Lauren Duprey, Chief Human Resource Officer, to further focus on employee well-being; Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer, to accelerate delivering against its purpose-led sustainability agenda; and Mwana Lugogo, Global Ethics and Compliance, to include data privacy. Takeda will also continue to have a focus on and commitment to its Oncology Business Unit and Japan Business Unit, along with its other critical functional areas such as Research and Development, Finance, Business Development, Human Resources, Quality, Ethics Compliance, Legal, Global Corporate Affairs, Corporate Strategy and Manufacturing with executive leadership of these areas continuing to report to Mr. Weber.